Skip to main content
Equibles

RDHL · RedHill Biopharma Ltd.

Track RDHL — free

Use RDHL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RDHL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.64 -0.01 (-1.29%) At close · Sep 11
Rebalance outlook locked
Market Cap
$3.92M
Shares
6.08M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.64 Open$0.66 Day$0.62–0.68 52W close$0.58–2.52 Avg vol 30d3.7M Short int8K · 0.1% float · 1.0d Short vol38% Last earningsMar 31, 2022 DataAug 2024–Sep 2026

Raw chart and full-history price indicators begin at the captured split on Aug 20, 2024; bars on opposite sides are not compared.

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-56.7%
Trailing year
Short interest
0.1%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −31%
below
Price vs 50-day avg −4%
below
RSI (14) 47
neutral
MACD trend Negative
52-week position 3%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +8%
trailing
6-month return −27%
trailing
YTD return −37%
this year
Relative strength −44%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-13% holders QoQ · +2 funds added
Insider flow Distributing
Net -$1.4K over 90 days · 100% sells
Short interest Falling
0.14% of float · ▼ -43.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
14 holders — mid 3-yr range
Squeeze score 35
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 97%
annualized · 1-yr
Max drawdown −77%
past year
ATR 15.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−31% Bearish
Price vs 50-day avg
−4% Neutral
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
3% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-13% holders QoQ · +2 funds added
Insider flow Distributing
Net -$1.4K over 90 days · 100% sells
Short interest Falling
0.14% of float · ▼ -43.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
14 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 3% Range high $3
vs 200-day avg -31% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RDHL
RedHill Biopharma Ltd.
this stock
$3.92M -37.4% — — 0.1%
TAK
Takeda Pharmaceutical Co Ltd
 $58.31B +17.1% — — 0.1%
GALDY
Galderma Group AG/ADR
 $44.03B -8.9% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $43.22B +18.8% +4.3% 60.8 3.2%
HLN
Haleon plc
 $40.41B -9.1% — — 0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
14
% held
5.2%
Net QoQ
-202.8K sh
Top holder
Yorkville Advisors Global…
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Falling
Shares short
8.4K
Days to cover
1.0d
Change
-6.3K sh
View
Short Volume
Short vol %
38%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
5.3K
Value
$3.9K
As of
Jul 17, 2026
View
Off-Exchange
Off-exchange %
53.0%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$1.4K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 1, 2026
This year
26
View
Exempt Offerings
Offering
$10.0M
Filed
Feb 5, 2024
View
Earnings & Events
Earnings Calls
Last call
Mar 31, 2022
View
Investor Relations
Latest news
RedHill Announces Transformationa…
Published
Sep 1, 2026
View

Performance

Raw-price comparisons begin at the captured split on Aug 20, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
RDHL -9.5% +8.4% -26.6% -28.3% -37.4%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -8.4% +10.1% -44.5% -28.0% -49.5%
Key facts CIK 1553846 CUSIP 757468301 13F (30d) 3 filings 3 filers Visit website Investor relations